CN108354917A - 含茶氨酸、磷脂酰丝氨酸和虾青素的缓解视疲劳的组合物 - Google Patents
含茶氨酸、磷脂酰丝氨酸和虾青素的缓解视疲劳的组合物 Download PDFInfo
- Publication number
- CN108354917A CN108354917A CN201810146015.7A CN201810146015A CN108354917A CN 108354917 A CN108354917 A CN 108354917A CN 201810146015 A CN201810146015 A CN 201810146015A CN 108354917 A CN108354917 A CN 108354917A
- Authority
- CN
- China
- Prior art keywords
- composition
- astaxanthin
- phosphatidylserine
- parts
- active constituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 title claims abstract description 60
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 55
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 33
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 33
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 33
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 33
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title claims abstract description 32
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title claims abstract description 32
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 229940026510 theanine Drugs 0.000 title claims abstract description 30
- 208000024891 symptom Diseases 0.000 claims abstract description 40
- 239000000470 constituent Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims abstract description 15
- 239000000047 product Substances 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 10
- 239000011648 beta-carotene Substances 0.000 claims description 8
- 229960002747 betacarotene Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- -1 flavine ester Chemical class 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000035807 sensation Effects 0.000 claims description 4
- 206010034960 Photophobia Diseases 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 235000012680 lutein Nutrition 0.000 claims description 3
- 239000001656 lutein Substances 0.000 claims description 3
- 229960005375 lutein Drugs 0.000 claims description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- 239000000571 coke Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 abstract description 7
- 206010057315 Daydreaming Diseases 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 10
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 244000299461 Theobroma cacao Species 0.000 description 5
- 206010047513 Vision blurred Diseases 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 235000019219 chocolate Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 208000027993 eye symptom Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 208000014733 refractive error Diseases 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000009847 Eye Foreign Bodies Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000168525 Haematococcus Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002350 accommodative effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/06—Products with modified nutritive value, e.g. with modified starch content
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及含茶氨酸、磷脂酰丝氨酸和虾青素的缓解视疲劳的组合物,属于医药健康领域。本发明提供了缓解视疲劳的组合物,其活性成分包括茶氨酸、磷脂酰丝氨酸和虾青素。人群试用结果表明,本发明组合物不仅针对视疲劳眼睛局部症状,更能够明显改善不同程度视疲劳引起的全身症状,如注意力不集中、记忆力下降等,缓解视疲劳效果显著,具有广阔的市场前景。
Description
技术领域
本发明涉及含茶氨酸、磷脂酰丝氨酸和虾青素的缓解视疲劳的组合物,属于医药健康领域。
背景技术
视疲劳又称眼疲劳,是以患者眼的自觉症状为基础,眼或全身器质性因素与精神(心理)因素相互交织的综合征,并非独立的眼病,因而常常被称为眼疲劳综合征(参见:1、李凤鸣.中华眼科学[M].北京:人民卫生出版社,2006,7~8;2、渠鸿颖等.视疲劳病因及其治疗的研究进展[J].中国中医眼科杂志,2003,14(1):59~61)。轻度视疲劳会在用眼后出现眼部酸、胀等眼部症状,休息后很快恢复;中度视疲劳会有明显的眼部症状,影响学习和工作;重度视疲劳除有明显的眼部症状和视作业不能持久外,还有记忆力减退、失眠等全身不适症状,干扰患者的视觉和生活质量,严重影响学习、工作和生活(参见:马越.花青素饮料缓解视疲劳作用的人体试验观察.中国食品学报[J].2015,8(15):8)。
大量的临床实践证明,屈光不正是视疲劳的主要原因之一,如远视、散光、近视患者,在未予矫正屈光不正时,看远或看近时动用较大的调节使睫状肌持续紧张造成患者的调节性视疲劳。另外,长时间近距离工作、工作或阅读环境照明不足等因素都可以导致人眼调节紧张,产生视疲劳。患者的精神状态和全身情况也与视疲劳的发生密切相关,精神压力大、体质衰弱的患者易产生视疲劳。
随着手机、平板电脑广泛进入人们的生活,人群全体用眼时间不断延长,近距离用眼强度增大,各年龄阶层视疲劳的发生率急速增多。能够改善视疲劳,并缓解由视疲劳带来的注意力、记忆力下降等问题的产品越来越受到消费者青睐。
目前,市面上改善视疲劳的产品通常仅针对蓝光损伤本身,对眼睛局部症状的改善效果不明显,而且并不能解决不同程度视疲劳引起的其他症状,如注意力不集中,记忆力下降等。因此,提供一种对视疲劳眼睛局部症状及全身症状缓解效果明显的产品,成为了一个亟待解决的问题。
发明内容
本发明的目的在于提供缓解视疲劳的组合物。
本发明提供了缓解视疲劳的组合物,活性成分包括茶氨酸、磷脂酰丝氨酸和虾青素。
进一步地,所述活性成分的重量配比为:茶氨酸20~1000份、磷脂酰丝氨酸10~1000份、虾青素1~250份。
进一步地,所述活性成分的重量配比为:茶氨酸100~400份、磷脂酰丝氨酸100~600份、虾青素4~25份。
优选地,所述活性成分的重量配比为:茶氨酸200~400份、磷脂酰丝氨酸200~500份、虾青素4~12份。
进一步优选地,所述活性成分的重量配比为:茶氨酸:磷脂酰丝氨酸:虾青素=(1~2):1:(0.04~0.12)。
进一步地,活性成分还包括DHA、叶黄素、叶黄素酯、(3R,3'R)-二羟基-β-胡萝卜素中一种或两种以上的混合物。
进一步地,活性成分还包括DHA 10~1000份。
进一步地,活性成分还包括叶黄素和/或叶黄素酯0.6~25份。
进一步地,活性成分还包括(3R,3'R)-二羟基-β-胡萝卜素0.2~10份。
进一步地,所述的组合物是各重量配比的活性成分,加入可接受的辅料或者辅助性成分制备而成的食品、保健品或药品。
进一步地,所述食品、保健品或药品为口服形式。
进一步地,所述食品或保健品为糖果、饮料、饼干、面包、果冻或膳食补充剂。
本发明提供了所述组合物的制备方法,包括如下步骤:取各重量配比的活性成分,加入食品、保健品或药品中可接受的辅料或者辅助性成分,即得。
本发明提供了所述组合物在制备缓解视疲劳的食品、保健品或药品中的用途。
进一步地,所述食品、保健品或药品具有缓解视疲劳所致眼睛局部症状和/或全身症状的功效。
进一步地,所述眼睛局部症状为眼酸痛、眼胀、畏光、视物模糊、眼干涩、异物感或流泪。
进一步地,所述全身症状为注意力下降、记忆力减退、焦虑或失眠。
虾青素,全称为3,3-二羟基-β胡萝卜素-4,4-酮,世界上最强的天然抗氧化剂之一,其清除自由基的能力是维生素C的6000倍,是维生素E的1000倍,是辅酶Q10的800倍,是一氧化氮的1800倍,是β-胡萝卜素功效的100倍。人类视网膜和中枢神经系统(脑)富含不饱和脂肪酸,因此,氧化产生的自由基很容易使其发生过氧化损伤。天然虾青素很容易通过血脑屏障和细胞膜,能有效地防止视网膜的氧化和感光细胞的损伤。本发明所述虾青素优选雨生红球藻来源。
本发明提供了缓解视疲劳的组合物。人群试用结果表明,本发明组合物不仅针对视疲劳眼睛局部症状,更能够明显改善不同程度视疲劳引起的全身症状,如注意力不集中、记忆力下降等,缓解视疲劳效果显著,具有广阔的市场前景。
具体实施方式
本发明具体实施方式中使用的原料、设备均为已知产品,通过购买市售产品获得。
本发明提供了缓解视疲劳的组合物,其活性成分包括茶氨酸、磷脂酰丝氨酸和虾青素。
茶氨酸可以抑制谷氨酸的毒性,保护神经元;具有促进脑波中α波产生的功能,从而引起轻松、愉快的感觉,缓解抑郁和焦虑情绪;降血压;促进注意力集中,增进反应速度和准确性。
神经细胞膜中含有大量的磷脂酰丝氨酸,其对神经细胞的维持、修复及功能具有重要作用。研究表明,补充磷脂酰丝氨酸能减缓甚至逆转痴呆或者与衰老相关的学习、情绪、记忆、注意力下降。
本发明通过将茶氨酸、磷脂酰丝氨酸和虾青素组合使用,不仅能够有效改善由视疲劳带来的严重影响工作与生活的全身不适症状,包括可以减轻或缓解注意力及记忆力下降问题,试用者普遍反映使用后情绪焦虑缓解明显,由眼疲劳引发的睡眠问题也明显缓解,而且,人群试用试验表明,本发明组合物改善视疲劳眼睛局部症状的效果较单用虾青素更加明显,比如,眼酸痛、眼胀、畏光、视物模糊、眼干涩、异物感、流泪等症状都能够得到一定程度的改善,对视疲劳的治疗效果十分显著。
实施例1本发明组合物的制备
原料重量配比:茶氨酸200~400份、磷脂酰丝氨酸200~500份、虾青素4~12份、DHA 100~400份、叶黄素酯5~15份、(3R,3'R)-二羟基-β-胡萝卜素1~5份。
制备方法:
1、按重量配比将茶氨酸、磷脂酰丝氨酸、虾青素、DHA、(3R,3'R)-二羟基-β-胡萝卜素、叶黄素酯混合均匀后加入糖浆搅拌均匀。
2、注模冷却成型后可按需制成硬质、奶糖、夹心、酥质、焦香(太妃)、充气、凝胶、胶基、压片、流质、膜片、花式等糖果类型,以及巧克力及巧克力制品、代可可脂巧克力和代可可脂巧克力制品、果冻(果汁型、果肉型、果味型、乳汁型等)等糖果制品。
实施例2本发明组合物的制备
原料重量配比:茶氨酸200~500份、磷脂酰丝氨酸200~500份、虾青素4~25份、DHA 100~400份、(3R,3'R)-二羟基-β-胡萝卜素1-10份、叶黄素酯1~25份。
制备方法:选择茶氨酸、磷脂酰丝氨酸、虾青素、(3R,3'R)-二羟基-β-胡萝卜素、叶黄素酯的原料混合,加入所需的处理水和30-45液态奶进行充分搅拌、溶解、均质,均质压力为25Mpa,再进行超高温灭菌,无菌包装,经检验合格后入库。
实施例3本发明组合物的制备
原料重量配比:茶氨酸200~600份、磷脂酰丝氨酸100~600份、虾青素1~25份、DHA 100~600份、(3R,3'R)-二羟基-β-胡萝卜素0.2-10份、叶黄素酯0.6~25份。
制备方法:选择茶氨酸、磷脂酰丝氨酸、虾青素、DHA、(3R,3'R)-二羟基-β-胡萝卜素、叶黄素酯,搅拌均匀,臭氧灭菌,灌装,可直接冲服或作为功能性辅料加入到其它食品中。
以下通过试验例证明本发明的有益效果。
试验例1本发明组合物缓解视疲劳及其相关症状的试用观察
设置9个试验组,分别按表2所示用量取茶氨酸、磷脂酰丝氨酸、虾青素,将其装入等大不透明胶囊,供眼疲劳患者试服,连续服用60天(表2对应每日服用量),观察试用效果。
根据《视疲劳诊疗专家共识》(2014年)诊断为视疲劳患者270例,症状包括视觉障碍:近距离工作或阅读不持久,出现暂时性视物模糊或重影;眼部不适:眼胀、眼痛、眼烧灼感、流泪、眼痒、眼异物感及眼眶疼痛。全身症状:易疲劳,头痛、头晕,记忆力减退,记忆力下降,焦虑,烦躁,以及其他神经官能症的症状。年龄18-65岁,随机分9组。根据国食药监保化[2012]107号《缓解视疲劳功能评价方法》制订视疲劳评定量表,见表1。全身症状进行单项评分:注意力下降评价(0分:能坚持专注工作或学习30分钟;1分:偶有注意力下降;2分:时有注意力下降;3分:经常有注意力下降);记忆力下降评价(0分:昨日事情全部能回忆;1分:偶有记忆力下降;2分:时有记忆力下降;3分:经常有记忆力下降);注:“偶有”是指1-2次/2天;“时有”是指1-3次/天;“经常”是指>3次/天。计算服用前、服用60天积分降低率:(治疗前总积分-治疗后总积分)/治疗前总积分×100%,治疗后积分降低率≥30%为有效。计算两组症状改善例数和两组症状改善有效率。症状改善有效率(%)计算方法为症状改善例数/试食例数×100。将两组症状改善有效率进行统计学检验。结果见表2。
表1视疲劳评定量表(半定量积分法)
注:“偶感”是指1-2次/2天;“时有”是指1-3次/天;“经常”是指>3次/天
表2症状积分改善有效率统计结果
试验组1仅添加了虾青素,试用结果表明其具有显著的缓解视疲劳眼睛局部症状的效果,服用60天后改善率达到56%,但起效较慢,服用1天有效率仅为44%。
试验组2、4~9在虾青素的基础上添加了磷脂酰丝氨酸和茶氨酸,结果明显加速了对眼睛局部症状的缓解效果,服用1天后显效更加明显,而且长期服用后对眼睛局部症状的缓解效果较试验组1更佳。试验组3效果降低,可能是由于虾青素的添加量较少,没有达到起效量。此外,加入磷脂酰丝氨酸和茶氨酸的试验组还能明显改善注意力和记忆力等全身症状。
从试验组2~9可以看出,茶氨酸、磷脂酰丝氨酸和虾青素在本发明限定的配比范围内(即茶氨酸20~1000份、磷脂酰丝氨酸10~1000份、虾青素1~250份)组合使用,均能够发挥明显的缓解视疲劳的作用,对影响视疲劳人群的眼睛局部症状和全身症状均有明显疗效。其中,优选比例为:茶氨酸200~400份、磷脂酰丝氨酸200~500份、虾青素4~12份。
在本实验中观察到,服用产品1天后,服用者出现明显的焦虑和烦躁降低、疲劳感减轻、视疲劳相关的全身症状如头痛、眼睛局部症状如视物模糊或重影明显减轻。长期效果在15~30天后逐渐显现,60天比较稳定,视疲劳相关的眼睛局部(眼胀、眼痛、眼干、烧灼感、异物感、视物模糊或重影)等有较好的改善作用。实验中还发现注意力和记忆力都有明显的改善作用。当茶氨酸、磷脂酰丝氨酸和虾青素复配后,既改善视疲劳全身症状又改善眼睛局部症状,抗视疲劳作用在各自领域中都有提升,尤其是最优比例范围效果较为明显。
Claims (12)
1.缓解视疲劳的组合物,其特征是:活性成分包括茶氨酸、磷脂酰丝氨酸和虾青素。
2.如权利要求1所述的组合物,其特征是:所述活性成分的重量配比为:茶氨酸20~1000份、磷脂酰丝氨酸10~1000份、虾青素1~250份。
3.如权利要求2所述的组合物,其特征是:所述活性成分的重量配比为:茶氨酸100~400份、磷脂酰丝氨酸100~600份、虾青素4~25份;优选地,所述活性成分的重量配比为:茶氨酸200~400份、磷脂酰丝氨酸200~500份、虾青素4~12份;进一步优选地,所述活性成分的重量配比为:茶氨酸:磷脂酰丝氨酸:虾青素=(1~2):1:(0.04~0.12)。
4.如权利要求1~3任意一项所述的组合物,其特征是:活性成分还包括DHA、叶黄素、叶黄素酯、(3R,3'R)-二羟基-β-胡萝卜素中一种或两种以上的混合物。
5.如权利要求1~4任意一项所述的组合物,其特征是:是各重量配比的活性成分,加入可接受的辅料或者辅助性成分制备而成的食品、保健品或药品。
6.如权利要求5所述的组合物,其特征是:所述食品、保健品或药品为口服形式。
7.如权利要求6所述的组合物,其特征是:所述食品或保健品为糖果、饮料、饼干、面包、果冻或膳食补充剂。
8.权利要求1~7任意一项所述组合物的制备方法,其特征是:包括如下步骤:取各重量配比的活性成分,加入食品、保健品或药品中可接受的辅料或者辅助性成分,即得。
9.权利要求1~7任意一项所述组合物在制备缓解视疲劳的食品、保健品或药品中的用途。
10.如权利要求9所述的用途,其特征是:所述食品、保健品或药品具有缓解视疲劳所致眼睛局部症状和/或全身症状的功效。
11.如权利要求10所述的用途,其特征是:所述眼睛局部症状为眼酸痛、眼胀、畏光、视物模糊、眼干涩、异物感或流泪。
12.如权利要求10所述的用途,其特征是:所述全身症状为注意力下降、记忆力减退、焦虑或失眠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810146015.7A CN108354917A (zh) | 2018-02-12 | 2018-02-12 | 含茶氨酸、磷脂酰丝氨酸和虾青素的缓解视疲劳的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810146015.7A CN108354917A (zh) | 2018-02-12 | 2018-02-12 | 含茶氨酸、磷脂酰丝氨酸和虾青素的缓解视疲劳的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108354917A true CN108354917A (zh) | 2018-08-03 |
Family
ID=63006063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810146015.7A Pending CN108354917A (zh) | 2018-02-12 | 2018-02-12 | 含茶氨酸、磷脂酰丝氨酸和虾青素的缓解视疲劳的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108354917A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103340911A (zh) * | 2013-06-14 | 2013-10-09 | 浙江工商大学 | 抗视觉疲劳保健品 |
CN108185427A (zh) * | 2018-02-11 | 2018-06-22 | 成都图径生物科技有限公司 | 含鱼眼、茶氨酸和磷脂酰丝氨酸的缓解视疲劳的组合物 |
-
2018
- 2018-02-12 CN CN201810146015.7A patent/CN108354917A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103340911A (zh) * | 2013-06-14 | 2013-10-09 | 浙江工商大学 | 抗视觉疲劳保健品 |
CN108185427A (zh) * | 2018-02-11 | 2018-06-22 | 成都图径生物科技有限公司 | 含鱼眼、茶氨酸和磷脂酰丝氨酸的缓解视疲劳的组合物 |
Non-Patent Citations (3)
Title |
---|
国家食品药品监督管理总局等组织编写: "《科学食用保健康:保健食品的选择》", 28 February 2015, 中国医药科技出版社 * |
金鑫等: "缓解视疲劳功能食品及其功效成分研究进展", 《食品科学》 * |
陆姣姣等: "磷脂酰丝氨酸和左旋茶氨酸对射击运动员心境状态、睡眠质量及中枢神经递质的影响", 《2016年全国运动生理与生物化学学术会议论文摘要汇编》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101595977B (zh) | 有益于眼睛明视持久度的配方食品及其应用 | |
CN102763847B (zh) | 一种具有缓解视疲劳的保健食品及其制备方法 | |
US20190335796A1 (en) | Optimized nutrient food | |
CN102065699A (zh) | 含脂质组合物及其使用方法 | |
CN102742656B (zh) | 一种缓解视力疲劳的奶茶及其制备方法 | |
CN108159036A (zh) | 含茶氨酸、磷脂酰丝氨酸和原花青素的缓解视疲劳的组合物 | |
CN111802476A (zh) | 一种提高儿童睡眠质量的奶粉及其制备方法 | |
CN104432036A (zh) | 缓解视疲劳的保健营养组合物及其制备方法与应用 | |
CN108078972A (zh) | γ-氨基丁酸在制备缓解视疲劳的食品、保健品或药品中的用途 | |
CN108294305A (zh) | 含原花青素的缓解视疲劳组合物 | |
CN108354175A (zh) | 含鱼眼、茶氨酸和γ-氨基丁酸的缓解视疲劳的组合物 | |
CN112715729A (zh) | 一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 | |
CN108354918A (zh) | 含茶氨酸、γ-氨基丁酸和原花青素的缓解视疲劳的组合物 | |
CN108324705A (zh) | 含茶氨酸、γ-氨基丁酸和花青素的缓解视疲劳的组合物 | |
CN104738781A (zh) | 一种新型黑玉米苦芥饮料的制备方法及其产品 | |
Beilin et al. | Vegetarian diet components, protein and blood pressure: which nutrients are important? | |
CN108042652A (zh) | 含枸杞、菊花和γ-氨基丁酸的缓解视疲劳的组合物 | |
CN108261472A (zh) | 含枸杞、菊花、γ-氨基丁酸和茶氨酸的缓解视疲劳的组合物 | |
CN108078974A (zh) | 含茶氨酸、γ-氨基丁酸和虾青素的缓解视疲劳的组合物 | |
CN108185427A (zh) | 含鱼眼、茶氨酸和磷脂酰丝氨酸的缓解视疲劳的组合物 | |
CN102488266B (zh) | 叶黄素木糖醇营养饮品及其制备方法 | |
CN108338364A (zh) | 含茶氨酸和虾青素的缓解视疲劳的组合物 | |
CN111227231A (zh) | 一种复合蓝莓叶黄素酯粉剂及其制备方法 | |
CN108210640A (zh) | 含茶叶提取物的缓解视疲劳组合物 | |
CN112385755A (zh) | 一种具有视力保健作用的果蔬饮品的制造工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180803 |
|
RJ01 | Rejection of invention patent application after publication |